Once-daily immunosuppression after liver transplant
Part of Immune system & allergy clinical trials.
This study tests whether taking immunosuppressive drugs (tacrolimus and mycophenolate mofetil) just once a day, instead of twice, works as well for people who recently had a liver transplant. The goal is to make the medication schedule easier and possibly safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You received your first liver transplant from a deceased donor and it was less than 4 weeks ago.
- You do not have any other transplanted organs, and you have not had a colon resection.
- You are not pregnant, breastfeeding, or planning to become pregnant, and you agree to use effective birth control if needed.
- You are not taking certain medications that could interfere with the study drugs (like HIV or hepatitis C protease inhibitors).
- You are able to understand the study and give your written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two long-acting forms of tacrolimus (Envarsus and Advagraf) to see how the body processes them after a kidney transplant. It aims to find the best way to use these medications to prevent organ rejection.
This trial tests whether switching from a standard anti-rejection medicine to a different one (everolimus) about a year after a liver transplant can help protect your new liver with fewer side effects. If you qualify, you will be monitored closely for a few years to see how well the new medicine works for you.
This study compares immediate-release versus extended-release tacrolimus (an anti-rejection medicine) to see if one form causes fewer tremors after a first liver transplant. It may help you and your care team choose the best form if tremors are a problem while your body adjusts after transplant.
This study looks at how tacrolimus (a rejection-preventing medicine) should be dosed in the first days to years after a kidney transplant. It may help personalize dosing by comparing different patient groups, including using genetic testing.
This trial looks at whether changing your maintenance anti-rejection medicine from Prograf (usually twice daily) to Envarsus (once daily) can help keep your liver and kidney function stable. It targets people who may be having kidney side effects, symptoms from tacrolimus, or trouble taking a twice-daily medicine.
This trial tests a special form of tacrolimus (Envarsus) taken once daily to prevent organ rejection in people who recently received a first lung transplant. The study will follow patients for at least 12 months.
Hear when a new Liver Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.